Compare Raymond James Financial, Inc. (RJF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Raymond James Financial, Inc. trades at $159.2 (market cap $30.51B), while State Street SPDR S&P Biotech ETF trades at $154.13 (market cap $10.11B). The key difference: Raymond James Financial, Inc. is far larger — about 3× State Street SPDR S&P Biotech ETF's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Raymond James Financial, Inc. for 75 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RJF | XBI | |
|---|---|---|
Market Cap | $30.51B | $10.11B |
Volume | 1,206,253 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $181.18 | $169.55 |
52-Week Low | $140.89 | $104.99 |
Typical Hold Time | 75 Days | 38 Days |
Enterprise Value | $24.37B | — |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.
The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
